First-Time Pharma Commercialization Launch Strategy for Success
Creating and Executing a Successful Drug Launch Strategy
“The idea of having a trusted partner was so important to us leading up to launch.”
Senior Vice President | Finance
Navigating Pharma Commercialization Strategy & Planning
We know how much weighs on the minds of pre-commercial pharmaceutical manufacturers. Clinical trials, government agency meetings, regulatory approval, and achieving that elusive PDUFA data and approval. Even once you’re ready to define your pharma commercialization strategy and prepare for launch, there’s all of the necessary planning lead time as well as numerous obstacles.
Insight into competitive market baskets trends around rebating, distribution, contracting, and patient support strategies
Understanding the role and economic position of payers, distributors, PBMs, and other ecosystem players
Building a credible, consensus forecast without historical data or industry benchmarks
Concern over how to ensure compliance given the ever-changing regulatory landscape and policies
Creating a right-sized, data-driven process for tracking product launch success
Creating a trusted, audit-ready net-pricing model without deep, in-house gross-to-net experts
IntegriChain and Blue Fin Group can ensure your drug launch strategy is on point for your product archetype and therapeutic class.
Creating a Tailored Pharma Launch Strategy for Your Unique Therapy
Successful pharmaceutical manufacturers create a sound pharma drug launch plan by choosing a partner that can outline and evolve strategy to market access execution, while maintaining agility to pivot along the path to commercialization. IntegriChain specializes in first-time drug launches and helps ensure an orderly preparation across critical business functions. Our ICyte platform combined with our advisory and drug launch strategy consulting services help solve these launch readiness challenges.
200 + product launch experts, supported by market-tested, archetype-based launch roadmaps
Comprehensive market benchmark data to measure the effectiveness of payer mix and channel strategy
Proven Commercial, Government, and Compliance, and Gross-to-Net Roadmap to Launch blueprints
Agile, flexible engagement coupled with “white-glove” care, and deep regulatory insights and expertise
Unified data, with pre-built connectors, offers a single source of truth
Business Process-as-a-Service (BPaaS) teams, with 200 + members, work as an adjunct to your pharma commercialization strategy teams
Measure Operational Performance Day 1 with actionable data
Audit-ready, market-proven gross-to-net systems and processes provide insight into net-price and daily operational performance
Having supported more than 60% of pharmaceutical product launches in the US over the past three years, we understand the variables.
CHECKLIST
Commercialization Checklist
Based on our experience with more than 100 Chief Commercial Officers and CEOs, here are 10 ways to pressure-test the readiness of your commercialization strategies
Blog
Best Practices: Redesigning the Perfect Launch
We asked three market access leaders with significant launch experience across multiple therapeutic categories from companies planning to launch or have launched their first product several questions about their launch journey.